CeQur Simplicity
CeQur Simplicity is a private medical device company offering a wearable bolus insulin delivery patch for adults with Type 1 or Type 2 diabetes on multiple daily injections. The FDA-cleared device is dispensed via US retail pharmacies.
- Company typePrivate
- Founded2018
- HeadquartersHorw, Switzerland
- Headcount101–250
- GTM typeB2C
- OfferingHardware or Manufacturing
What CeQur Simplicity does
CeQur Simplicity is a privately held medical device company that designs, manufactures, and commercializes a wearable, disposable bolus insulin delivery patch for adults aged 21 and older with Type 1 or Type 2 diabetes who are on multiple daily injection (MDI) regimens. The company's core technology is a thin, low-profile patch that delivers rapid-acting mealtime insulin via a hidden, flexible cannula, eliminating the need for needle handling at each meal. The device holds 15 patents covering its bolus-only architecture, dosing lock safety mechanism, hidden cannula insertion, and two-button user interface, and is FDA 510(k)-cleared for up to 7 days of continuous wear with the most recent clearance extending wear duration from 4 days and adding a 1-unit dosing variant for more precise titration. The patch is compatible with Eli Lilly's Humalog (insulin lispro) and Novo Nordisk's NovoLog (insulin aspart) U-100 rapid-acting insulin analogues, which patients fill into the device themselves.
The company operates a prescription-based, pharmacy-benefit commercial model in the United States. Revenue is generated through hardware sales of the patch (sold as an 8-pack), dispensed via retail pharmacies with coverage on more than 85% of claims as a pharmacy benefit as of mid-2026. Commercial distribution combines an expanding US field sales force targeting endocrinologists, primary care physicians, and certified diabetes educators; clinical diabetes specialists supporting prescriber education; and the CeQur Cares inside-sales patient support team handling onboarding, insurance navigation, and copay enrollment (commercially insured patients can access a savings card limiting out-of-pocket to under $35 per month). Government channel sales to the VA and DoD are executed through Lovell Government Services, a Service-Disabled Veteran-Owned Small Business partner.
CeQur is headquartered in Horw, Switzerland, with US operational headquarters in Greenville, South Carolina, and a 40,000 sq ft automated cleanroom manufacturing facility in Marlborough, Massachusetts, completed in Q4 2024 with capacity to support 100,000 patients. The company has raised more than $335 million across five equity rounds, including a $100 million Series C5 in April 2021, a $120 million equity financing in January 2025, and a $100 million Series E in June 2026 led by Sanofi Ventures. More than 6,000 patients were actively using the device by mid-2025, and the patch has cumulatively replaced more than 10 million mealtime injections since launch. The commercial organization is led by CEO Bradley Paddock (appointed June 2019), CFO Mike Rubino, Chief Commercial Officer Lisa Furnish, and VP of Sales Darin Row (joined March 2025 from Dexcom).
CeQur Simplicity firmographics
Firmographics- Name
- CeQur Simplicity
- Legal name
- CeQur SA
- Website
- https://myceqursimplicity.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- CeQur Simplicity is a private medical device company offering a wearable bolus insulin delivery patch for adults with Type 1 or Type 2 diabetes on multiple daily injections. The FDA-cleared device is dispensed via US retail pharmacies.
- Ownership category
- akta.pro rank
CeQur Simplicity industry classification
Industry- Product category
- Wearable Insulin Delivery Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)
- akta.pro secondary industry
- Insulin Pumps & Patch Pumps (HLAHAIAG)
Keywords
Where CeQur Simplicity is headquartered
LocationHeadquarters
- HQ city
- Horw
- HQ country
- Switzerland
- HQ region
- Europe
Offices3 records
Markets served
CeQur Simplicity business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Insulin Delivery Device — Prescription Medical Device Sales: CeQur generates revenue primarily through the sale of its Simplicity bolus insulin delivery patch. The device is a prescription-only Class II medical device dispensed through retail pharmacies. Patients obtain the device via prescription from their healthcare provider and fill it at a pharmacy. Revenue is driven by prescription volume, patient adherence, and payer coverage. Commercial insurance, Medicare Part D, and cash-pay patients all contribute.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Monthly | Standard prescription — retail pharmacy (commercial insurance) |
| Unit Pricing | Monthly | Standard prescription — retail pharmacy (uninsured / cash pay) |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
CeQur Simplicity product offering
Product offeringCore offering
CeQur Simplicity develops and manufactures a wearable, disposable bolus insulin delivery patch designed to replace multiple daily mealtime injections for adults with Type 1 or Type 2 diabetes. The device delivers rapid-acting insulin (Humalog or NovoLog) on demand via a hidden flexible cannula using a simple two-button interface, with FDA-cleared wear durations of up to 7 days.
Product overview
CeQur Simplicity is a single-product medical device company offering the CeQur Simplicity wearable insulin patch as its core product. The portfolio consists of the CeQur Simplicity patch (available in 2-unit and 1-unit dosing variants, with wear duration extended from 4 to 7 days), the reusable Inserter accessory, and the CeQur Cares patient support program. The patch is filled by users with their own prescribed rapid-acting insulin (Humalog U-100 or NovoLog U-100) and delivers on-demand bolus insulin subcutaneously via a flexible cannula. The company also offers a copay savings card for commercially insured patients. The product is sold as an 8-pack of 4-day patches (now expanding to 7-day variants) and is covered as a pharmacy benefit by most commercial and Medicare Part D plans.
Differentiator
Problem solved
Functional benefit
Products and services
- CeQur Simplicity Wearable Insulin Patch A disposable wearable patch that delivers mealtime and correction bolus insulin via a soft, flexible cannula. Users fill the patch with up to 200 units of rapid-acting insulin (Humalog U-100 or NovoLog U-100) and self-administer 2-unit doses by squeezing two buttons. The patch is FDA-cleared for wear up to 7 days and eliminates the need for multiple daily injections.
- CeQur Simplicity 1-Unit Dosing Device A variant of the CeQur Simplicity patch delivering 1-unit increments of rapid-acting insulin for more precise titration in patients requiring tighter glycemic control or lower mealtime insulin doses.
- CeQur Simplicity Inserter A reusable handheld device used to apply the CeQur Simplicity patch to the abdomen. Measures 3.7 inches long, 2.2 inches wide, and 1.8 inches high, weighing 2.5 ounces, and is cleanable with soapy water.
Quantifiable outcome
- A1C reduction of 1.7% in adults with Type 1 or Type 2 diabetes on multiple daily injections
- +1 more outcomes
Companies that use CeQur Simplicity
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
CeQur Simplicity technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
CeQur Simplicity partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Lovell Government ServicescoreLovell Government Services is a Service-Disabled Veteran-Owned Small Business (SDVOSB) that serves as CeQur's channel partner for sales into the Veterans Affairs (VA) and Department of Defense (DoD) healthcare systems. CeQur has partnered with Lovell to expand access to the Simplicity bolus insulin delivery patch for eligible veterans and active-duty military patients with diabetes managed on multiple daily injections. The partnership enables CeQur to comply with government contracting requirements and access a specialized distribution channel.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
CeQur Simplicity competitors and assessment
Company assessmentDirect peers
- Insulet Corporation: Maker of the Omnipod tubeless patch pump, the closest direct competitor to CeQur in the wearable insulin delivery category. Omnipod 5 is an integrated AID system, while CeQur is bolus-only — both target patients seeking tubeless, on-body insulin delivery via patch form factor.
- Tandem Diabetes Care: Manufacturer of the t:slim X2 insulin pump with Control-IQ AID technology. Competes for the same insulin-requiring patient population, though delivered via tubed pump rather than patch form factor. Tandem is also an investor in CeQur (Series C5).
- MannKind Corporation (V-Go): Markets V-Go, a wearable basal-bolus insulin patch that delivers continuous basal and on-demand bolus insulin. Most directly comparable by mechanism (wearable patch, mechanical bolus delivery) though V-Go provides basal coverage as well.
- Ypsomed: Swiss manufacturer of the mylife YpsoPump insulin pump and a long-standing CeQur investor. Comparable wearable/concealable insulin delivery device maker and a strategic partner/investor with potential channel conflict.
Broad incumbents
- Medtronic Diabetes: Incumbent insulin pump manufacturer (MiniMed 780G AID system) with dominant hospital channel relationships and integrated CGM (Guardian) offering. Far larger and broader portfolio than CeQur's single patch product.
- Dexcom: Continuous glucose monitor (CGM) market leader whose devices are increasingly integrated with insulin pump AID systems. Dexcom is part of the broader diabetes technology ecosystem CeQur operates in, and Darin Row (CeQur's VP Sales) joined from Dexcom.
- Abbott Diabetes Care: Maker of FreeStyle Libre, the global CGM volume leader. Increasingly moving toward automated insulin delivery through partnerships (e.g., Tandem, Insulet), making Abbott a powerful adjacent incumbent shaping the same patient ecosystem.
- Eli Lilly: Major insulin manufacturer (Humalog) and GLP-1 producer. CeQur Simplicity is FDA-cleared for use with Humalog, making Lilly a critical compatibility partner; Lilly's own diabetes device ambitions (e.g., connected pen ecosystem) create adjacent competition.
- Novo Nordisk: Major insulin manufacturer (NovoLog) and GLP-1 leader. CeQur Simplicity is cleared for use with NovoLog, making Novo Nordisk a key compatibility partner; the company's growing diabetes technology footprint creates ecosystem-level competitive dynamics.
Emerging players
- Bigfoot Biomedical: Diabetes-focused startup developing smart insulin pen systems and AID integrations. Targets the MDI population similar to CeQur but via connected pen rather than patch, positioning as an emerging alternative in the same 'simplify MDI' category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
CeQur Simplicity social profiles
Digital presenceCeQur Simplicity compliance and trust
Trust signalCompliance2 records
CeQur Simplicity financial estimates
Financial estimateRevenue estimate
Valuation estimate
CeQur Simplicity leadership team
Management profileNumber of profiles
Profiles10 records
CeQur Simplicity funding detail
Funding detailFunding overview
Funding rounds6 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CeQur Simplicity M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CeQur Simplicity
What does CeQur Simplicity do?
CeQur Simplicity develops and manufactures a wearable, disposable bolus insulin delivery patch designed to replace multiple daily mealtime injections for adults with Type 1 or Type 2 diabetes. The device delivers rapid-acting insulin (Humalog or NovoLog) on demand via a hidden flexible cannula using a simple two-button interface, with FDA-cleared wear durations of up to 7 days.
Is CeQur Simplicity a public or private company?
CeQur Simplicity is a private company. It is classified as venture growth investor backed and is currently operating.
When was CeQur Simplicity founded?
CeQur Simplicity was founded in 2018. It employs 101 to 250 people.
Where is CeQur Simplicity based?
CeQur Simplicity is headquartered in Horw, Switzerland, in the Europe region.
How does CeQur Simplicity make money?
One revenue line is on record: insulin Delivery Device — Prescription Medical Device Sales.
Who are CeQur Simplicity's main competitors?
Direct peers on record are Insulet Corporation, Tandem Diabetes Care, MannKind Corporation (V-Go) and Ypsomed. Broad incumbents are Medtronic Diabetes, Dexcom, Abbott Diabetes Care, Eli Lilly and Novo Nordisk. Bigfoot Biomedical is listed as an emerging player.
Does CeQur Simplicity have an API?
No public API is recorded for CeQur Simplicity.
What industry is CeQur Simplicity in?
CeQur Simplicity's product category is Wearable Insulin Delivery Devices. Its primary akta.pro industry code is HLAHAHAC, Patch Pumps & Wearable Insulin Delivery, with a secondary code of HLAHAIAG, Insulin Pumps & Patch Pumps. Its NAICS code is 3391 and its SIC code is 3842.